(Q42255546)

English

The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study

scientific article published on 15 November 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1 reference

based on heuristic

inferred from title

Cornelis J. M. Melief

17

object named as

Cornelis J M Melief

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Sjoerd H van der Burg

19

object named as

Sjoerd H van der Burg

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

author name string

Peggy J de Vos van Steenwijk

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Mariette I E van Poelgeest

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Tamara H Ramwadhdoebe

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Margriet J G Löwik

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Dorien M A Berends-van der Meer

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Caroline E van der Minne

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Nikki M Loof

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Linda F M Stynenbosch

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Lorraine M Fathers

9

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

A Rob P M Valentijn

10

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Jaap Oostendorp

11

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Elisabeth M Osse

12

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Gert Jan Fleuren

13

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Linda Nooij

14

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Marjolein J Kagie

15

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Bart W J Hellebrekers

16

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Marij J P Welters

18

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Gemma G Kenter

20

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

publication date

15 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

147-160

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

"MIATA"-minimal information about T cell assays

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

Therapeutic vaccination against human papilloma virus induced malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

TLR ligand-peptide conjugate vaccines: toward clinical application

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1499-2

21 January 2018

Identifiers

10.1007/S00262-013-1499-2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42255546&oldid=2205170798"